STOCK TITAN
  1. Home
  2. Sec-filings
  3. KALA
  4. [Form 4] KALA BIO, Inc. Insider Trading Activity

KALA Bio Executive's Planned Stock Sale Tied to RSU Tax Requirements

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Kala Bio insider trading activity reported: Head of Research and Development and Chief Medical Officer Romulus K. Brazzell sold 5,251 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share (range: $3.87-$4.12).

Key details:

  • Sale executed under a 10b5-1 trading plan established November 9, 2020
  • Transaction purpose: Cover tax withholding obligations from RSU vesting granted June 22, 2023
  • Post-transaction holdings: 82,698 shares, including 35,952 unvested RSUs
  • Transaction form: Direct ownership

The sale was made in compliance with SEC regulations and followed a pre-established trading plan, indicating a routine transaction rather than a strategic investment decision.

Positive

  • None.

Negative

  • None.
Insider Brazzell Romulus K
Role SEE REMARKS
Sold 5,251 shs ($21K)
Type Security Shares Price Value
Sale Common Stock 5,251 $4.01 $21K
Holdings After Transaction: Common Stock — 82,698 shares (Direct)
Footnotes (1)
  1. This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on June 22, 2023. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Includes 35,952 unvested RSUs.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Brazzell Romulus K
(Last) (First) (Middle)
C/O KALA BIO, INC.
1167 MASSACHUSETTS AVENUE
(Street)
ARLINGTON MA 02476
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KALA BIO, Inc. [ KALA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SEE REMARKS
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/24/2025 S 5,251(1) D $4.01(2) 82,698(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on June 22, 2023.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
3. Includes 35,952 unvested RSUs.
Remarks:
Head of Research and Development and Chief Medical Officer
/s/ Mary Reumuth, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many KALA shares did Romulus Brazzell sell on June 24, 2025?

Romulus Brazzell, KALA's Head of Research and Development and Chief Medical Officer, sold 5,251 shares of common stock on June 24, 2025 at a weighted average price of $4.01 per share.

What was the purpose of KALA insider Brazzell's stock sale in June 2025?

The sale was made pursuant to a 10b5-1 trading plan adopted on November 9, 2020, specifically to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs) that were granted on June 22, 2023.

What is the price range at which KALA shares were sold in this Form 4 transaction?

The shares were sold in multiple transactions at prices ranging from $3.87 to $4.12 per share, with a weighted average price of $4.01.

How many KALA shares does Romulus Brazzell own after the June 2025 transaction?

Following the reported transaction, Brazzell beneficially owns 82,698 shares directly, which includes 35,952 unvested restricted stock units (RSUs).

What position does Romulus Brazzell hold at KALA Bio?

Romulus Brazzell serves as the Head of Research and Development and Chief Medical Officer at KALA Bio, Inc.